Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

TVF Communications

- PMLiVE

Presenting Outstanding Outcomes from HCP Education in Multiple Myeloma at IMS in Athens

From September 27-30, members of the Medscape Education Global team were in Athens, Greece sharing 5 posters at the International Myeloma Society Annual Meeting, 2023.The posters presented the outcomes and...

Medscape Education

Top 10 benefits of virtual advisory boards: Save Time and Resources

We've broken down the top ten benefits of why virtual advisory boards are superior to in-person and hybrid advisory boards. #1. Countless Hours of Time-savings and Substantially Reduced Costs We’ll...

Impetus Digital

- PMLiVE

NIHR launches new framework to highlight health progress outcomes

Over 400 partners and stakeholders collaborated to develop the new framework

- PMLiVE

UKHSA secures UK-based vaccine deal for future influenza pandemics

CSL Sequiris will be ready to produce over 100 million influenza pandemic vaccines

- PMLiVE

Johns Hopkins and National Cancer Unit develop new genetic risk-scoring method for major diseases

The new method analysed over five million people from diverse populations

- PMLiVE

Novo Nordisk and Valo Health agree deal worth up to $3.3bn to develop cardiovascular treatments

The companies will work together to develop new cardiovascular treatments

- PMLiVE

Landscape review reveals £1.1bn of UK funding for rare diseases

The report focuses on future funding and needs for those with rare diseases

- PMLiVE

New diagnosis pathway has been launched to mark European Myeloma Day

The Myeloma Diagnosis Pathway aims to improve early diagnosis for patients

- PMLiVE

Cancer Research UK partners with French cancer institute

Both organisations will support the global Cancer Grand Challenges initiative

- PMLiVE

Impacting Lives with Rare Disease Education

Education on rare diseases is crucial. Estimates suggest there are approximately 10,000 rare diseases, with 263–446 million people affected worldwide.Since its launch in September 2022, the Medscape Pathways in Rare...

Medscape Education

- PMLiVE

Sandoz biosimilar receives EC approval to treat MS

Tyruko is the first and only biosimilar treatment for relapsing-remitting MS in Europe

- PMLiVE

Pfizer’s Abrysvo RSV vaccine recommended by US CDC for infants

The recommendation allows Abrysvo to be given to pregnant women from 32 to 36 weeks

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links